GlassScriptPhysician profile
Meg Anne Whelan
NPI 1841348455
$3,534.88
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2020: $506 · 2021: $490 · 2022: $784 · 2023: $373 · 2024: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $897.61 | 2019-2024 | Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $337.64 | 2019-2024 | Dupixent |
| Optinose US, INC. | $310.20 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $309.97 | 2019-2024 | |
| Glaxosmithkline, LLC. | $306.48 | 2019-2024 | Nucala |
| Kaleo, INC. | $254.15 | 2019-2024 | Auvi-Q |
| Genzyme Corporation | $240.25 | 2019-2024 | |
| Pfizer INC. | $233.90 | 2019-2022 | |
| Amgen INC. | $173.98 | 2022-2024 | Tezspire |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $149.13 | 2019-2021 | |
| Genentech USA, INC. | $50.53 | 2020-2024 | Xolair |
| Uswm, LLC | $45.58 | 2021 | |
| Leo Pharma INC. | $40.02 | 2022-2023 | Adbry |
| Abbvie INC. | $36.20 | 2022-2023 | Rinvoq |
| Alk-Abello, INC | $28.96 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $25.94 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.07 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.95 | 2023 | Spiriva Respimat |
| Eyevance Pharmaceuticals LLC | $14.15 | 2021 | |
| Hikma Pharmaceuticals USA | $13.14 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meg Whelan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.